Baxalta’s Antibody Patent Held Invalid under Amgen’s Enablement Standard by the Federal Circuit

In Baxalta, Inc. v. Genentech, Inc., the Court of Appeals for the Federal Circuit upheld a summary judgment finding from the District of Delaware (Judge Timothy B. Dyk) that claims 1-4, 19 and 20 of Baxalta’s patent directed to Factor IX were invalid for lack of enablement based on the Supreme Court’s finding in Amgen v Sanofi….
By: Haug Partners LLP
Previous Story

MasTec Employees May Be the Victim of MOVEit Data Breach Occurring at Delta Dental

Next Story

An Endeavor to Facilitate Free Movement of Data From China